Advancing anti-PACAP therapies for the prevention of migraine and other headache disorders.
About
Slate Medicines is a biotechnology company focused on developing novel anti-PACAP (Pituitary Adenylate Cyclase-Activating Polypeptide) therapies for the prevention and treatment of migraine and other severe headache disorders. The company launched with a significant Series A financing to support its therapeutic pipeline.
Tags
Performance
Company Timeline
No timeline data for this period
Score Breakdown
51Traction
40Team
30Visibility
6Profile
75Community
15Discussion (0)
Join the discussion
No comments yet. Be the first to share your thoughts!
Frequently Asked Questions
What does Slate Medicines do?
Slate Medicines is a biotechnology company focused on developing novel anti-PACAP (Pituitary Adenylate Cyclase-Activating Polypeptide) therapies for the prevention and treatment of migraine and other severe headache disorders. The company launched with a significant Series A financing to support its therapeutic pipeline.
How much funding has Slate Medicines raised?
Slate Medicines has raised a total of $130M in funding. The most recent round on record is Series A.
Where is Slate Medicines headquartered?
Slate Medicines is headquartered in Cambridge, Massachusetts, United States.
When was Slate Medicines founded?
Slate Medicines was founded in 2024.
What industry does Slate Medicines operate in?
Slate Medicines operates in Biotechnology, Pharmaceuticals, Therapeutics, Healthcare.
Similar Startups